Abstract

COMPARISON OF ANTIPLATELET THERAPY IN ACS PATIENTS WHO UNDERWENT PTCA IN A TERTIARY CARE HOSPITAL

Sherin Babu*, Athira James, Georley George, Dr. Rini Susan Varghese, Dr. Mahesh N. M. and Dr. Praveen Kumar

Abstract

Background: Antiplatelet therapy is the major therapy given for Acute Coronary Syndrome patients who had underwent Percutaneous Transluminal Coronary Angioplasty. Studies related to proper selection of antiplatelet therapy considering their benefits and risks in patients after PTCA are limited. Objective: To compare the prescribed antiplatelet therapy in ACS patients by assessing the primary and secondary cardiovascular events occurred after PTCA. Method: The proposed retrospective cohort study was conducted in 180 patients admitted in Aster CMI hospital, Hebbal, Bangalore for a period of 6 months. Result: Among the patients included in the study, 11.1% of patients were prescribed with monotherapy, 68.3% with dual therapy, 20.6% with triple therapy. The incidences of primary (Myocardial infarction, Unstable angina, Congestive heart failure and cardiovascular death) endpoints (80%) and secondary (dyspnea, bleeding) endpoints (20%) were assessed and the occurrence of these endpoints in patients after PTCA were comparatively less with Dual Antiplatelet Therapy. In high-risk patients, Aspirin-Ticagrelor combination (41.9%) was prescribed more when compared to other antiplatelet therapies based on their Left Ventricular Ejection Fraction. Conclusion: After PTCA, DAPT was prescribed more than other antiplatelet therapies. Occurrences of cardiovascular complications were comparatively less in patients on Aspirin-Ticagrelor combination therapy. The study concluded that Aspirin-Ticagrelor combination is the safest and better therapeutic option with minimum cardiovascular events.

Keywords: ACS – Acute Coronary Syndrome, PTCA – Percutaneous Coronary Angioplasty, DAPT – Dual Antiplatelet Therapy.